Johnson & Johnson is raising its full-year profit forecast as drug sales outpace devices
The health care giant now expects adjusted EPS of $11.05 to $11.15 for 2026, and is leaning toward spinning off its orthopedics unit
We haven't written up this one. Quartz has the full story — the link below goes straight to it.